Catriona Jane Bhagra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Catriona Jane Bhagra has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Sai Bhagra
Royal Papworth Hospital, Cambridge, United Kingdom
11 shared publications Mathew Sermer
Department of Obstetrics & Gynecology, Division of Maternal Fetal Medicine, University of Toronto, Sinai Health System, Toronto, Canada
5 shared publicationsG. MacGowan
3 shared publicationsG. Parry
3 shared publications- Gareth Parry
Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, UK
3 shared publications - Rachel Maya Wald
Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada; Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, Canada; Division of Cardiology, Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, ON Canada
3 shared publications
Latest Publications
- Open Access
- 6 May 2026
- Published by Elsevier in Pregnancy Hypertension
- Vol. 44, 101480
The impact of maternal postpartum body mass index on cardiovascular health at 1 year following pregnancy in Uganda
- 6 May 2026
- Published by Elsevier in Pregnancy Hypertension
- Vol. 44, 101480
Open AccessThe impact of maternal postpartum body mass index on cardiovascular health at 1 year following pregnancy in Uganda
- 4 November 2025
- Published by SAGE Publications in Obstetric Medicine
- Vol. 19 (3) , 186-189
Complete heart block in pregnancy: Review of current literature and case report
Complete heart block (CHB) in pregnancy is a rare condition, with acquired cases being particularly unusual. The management of CHB is guided by the underlying aetiology, symptoms, and associated risk factors, requiring careful consideration of both maternal and fetal well-being. This review examines the causes and pathophysiological mechanisms of CHB and discusses the pregnancy-related haemodynamic and hormonal changes that may exacerbate cardiac conduction abnormalities. We present the case of a 25-year-old woman diagnosed with acquired CHB at 18 weeks and 6 days of gestation, who underwent successful dual-chamber pacemaker implantation. This case illustrates the key aspects of managing CHB in pregnancy, including comprehensive diagnostic evaluation and careful delivery planning. Given the complexity of this clinical scenario, a multidisciplinary approach, including cardiologists, obstetricians and anaesthetists, is essential for optimising maternal and fetal outcomes. Further research is required to refine clinical guidelines and develop recommendations regarding long-term patient care and the management of subsequent pregnancies.
- 4 November 2025
- Published by SAGE Publications in Obstetric Medicine
- Vol. 19 (3) , 186-189
Complete heart block in pregnancy: Review of current literature and case report
Complete heart block (CHB) in pregnancy is a rare condition, with acquired cases being particularly unusual. The management of CHB is guided by the underlying aetiology, symptoms, and associated risk factors, requiring careful consideration of both maternal and fetal well-being. This review examines the causes and pathophysiological mechanisms of CHB and discusses the pregnancy-related haemodynamic and hormonal changes that may exacerbate cardiac conduction abnormalities. We present the case of a 25-year-old woman diagnosed with acquired CHB at 18 weeks and 6 days of gestation, who underwent successful dual-chamber pacemaker implantation. This case illustrates the key aspects of managing CHB in pregnancy, including comprehensive diagnostic evaluation and careful delivery planning. Given the complexity of this clinical scenario, a multidisciplinary approach, including cardiologists, obstetricians and anaesthetists, is essential for optimising maternal and fetal outcomes. Further research is required to refine clinical guidelines and develop recommendations regarding long-term patient care and the management of subsequent pregnancies.
- 1 April 2025
- Published by SAGE Publications in JRSM Cardiovascular Disease
- Vol. 14
Pregnancy and breastfeeding in the mother with cardiomyopathy
Cardiomyopathies are diseases of the heart muscle, characterised by structural and functional abnormalities of the myocardium that are not caused by ischemia, valvular problems or congenital heart disease. They are responsible for one-third of pregnancy-related cardiovascular deaths. A woman may enter pregnancy with a pre-existing diagnosis, or the cardiomyopathy may emerge or develop de novo during pregnancy. The most common cardiomyopathies encountered in pregnancy are dilated cardiomyopathy, hypertrophic cardiomyopathy and peripartum cardiomyopathy. All cardiomyopathies can be complicated by clinical heart failure, arrhythmia and thromboembolic events. Pregnancy may be poorly tolerated in women with dilated cardiomyopathy. New York Heart Association Class (NYHA) III/IV symptoms, and severe left ventricular dysfunction are the main determinants of adverse maternal outcomes. Peripartum cardiomyopathy is a diagnosis of exclusion with symptom onset towards the end of pregnancy, or within a few months following delivery. The management of heart failure and arrhythmias is based upon established guidelines, tailored for the unique considerations of pregnancy. Contemporary data suggests that recovery in cardiac function by 12 months is approximately 60–70% for the peripartum group. Maternal cardiovascular risk can be determined using specific risk-predictive scores. All patients with cardiomyopathy who wish to consider pregnancy should be offered individualized pre-conception and contraceptive counselling by a multidisciplinary team. This article reviews the management of women with cardiomyopathy during pregnancy and breastfeeding, focusing on the essential role of the multidisciplinary team at every stage of pregnancy and postpartum period to improve the maternal, fetal, and neonatal outcomes.
- 1 April 2025
- Published by SAGE Publications in JRSM Cardiovascular Disease
- Vol. 14
Pregnancy and breastfeeding in the mother with cardiomyopathy
Cardiomyopathies are diseases of the heart muscle, characterised by structural and functional abnormalities of the myocardium that are not caused by ischemia, valvular problems or congenital heart disease. They are responsible for one-third of pregnancy-related cardiovascular deaths. A woman may enter pregnancy with a pre-existing diagnosis, or the cardiomyopathy may emerge or develop de novo during pregnancy. The most common cardiomyopathies encountered in pregnancy are dilated cardiomyopathy, hypertrophic cardiomyopathy and peripartum cardiomyopathy. All cardiomyopathies can be complicated by clinical heart failure, arrhythmia and thromboembolic events. Pregnancy may be poorly tolerated in women with dilated cardiomyopathy. New York Heart Association Class (NYHA) III/IV symptoms, and severe left ventricular dysfunction are the main determinants of adverse maternal outcomes. Peripartum cardiomyopathy is a diagnosis of exclusion with symptom onset towards the end of pregnancy, or within a few months following delivery. The management of heart failure and arrhythmias is based upon established guidelines, tailored for the unique considerations of pregnancy. Contemporary data suggests that recovery in cardiac function by 12 months is approximately 60–70% for the peripartum group. Maternal cardiovascular risk can be determined using specific risk-predictive scores. All patients with cardiomyopathy who wish to consider pregnancy should be offered individualized pre-conception and contraceptive counselling by a multidisciplinary team. This article reviews the management of women with cardiomyopathy during pregnancy and breastfeeding, focusing on the essential role of the multidisciplinary team at every stage of pregnancy and postpartum period to improve the maternal, fetal, and neonatal outcomes.
- 1 August 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (8) , e012085
Beyond Survival: Empowering Women by Enhancing Reproductive Health Education for Heart Transplant Recipients
- 1 August 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (8) , e012085
Beyond Survival: Empowering Women by Enhancing Reproductive Health Education for Heart Transplant Recipients
- 26 October 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (3) , e1-e42
Reproductive health after thoracic transplantation: An ISHLT expert consensus statement
- 26 October 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (3) , e1-e42
Reproductive health after thoracic transplantation: An ISHLT expert consensus statement
- 1 October 2020
- Published by Elsevier in International Journal of Cardiology
- Vol. 317, 63-69
Cardiovascular and abdominal flow alterations in adults with morphologic evidence of liver disease post Fontan palliation
- 1 October 2020
- Published by Elsevier in International Journal of Cardiology
- Vol. 317, 63-69
Cardiovascular and abdominal flow alterations in adults with morphologic evidence of liver disease post Fontan palliation
- Open Access
- 1 July 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (13) , 828
A review of the management of patients with advanced heart failure in the intensive care unit
Despite progress in the medical and device therapy for heart failure (HF), the prognosis for those with advanced HF remains poor. Acute heart failure (AcHF) is the rapid development of, or worsening of symptoms and signs of HF typically leading to hospitalization. Whilst many HF decompensations are managed at a ward-based level, a proportion of patients require higher acuity care in the intensive care unit (ICU). Admission to ICU is associated with a higher risk of in-hospital mortality, and in those who fail to respond to standard supportive and medical therapy, a proportion maybe suitable for mechanical circulatory support (MCS). The optimal pre-operative management of advanced HF patients awaiting durable MCS or cardiac transplantation (CTx) is vital in improving both short and longer-term outcomes. This review will summarize the clinical assessment, hemodynamic profiling and management of the patient with AcHF in the ICU. The general principles of pre-surgical optimization encompassing individual systems (the kidneys, the liver, blood and glycemic control) will be discussed. Other factors impacting upon post-operative outcomes including nutrition and sarcopenia and pre-surgical skin decolonization have been included. Issues specific to durable MCS including the assessment of the right ventricle and strategies for optimization will also be discussed.
- 1 July 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (13) , 828
Open AccessA review of the management of patients with advanced heart failure in the intensive care unit
Despite progress in the medical and device therapy for heart failure (HF), the prognosis for those with advanced HF remains poor. Acute heart failure (AcHF) is the rapid development of, or worsening of symptoms and signs of HF typically leading to hospitalization. Whilst many HF decompensations are managed at a ward-based level, a proportion of patients require higher acuity care in the intensive care unit (ICU). Admission to ICU is associated with a higher risk of in-hospital mortality, and in those who fail to respond to standard supportive and medical therapy, a proportion maybe suitable for mechanical circulatory support (MCS). The optimal pre-operative management of advanced HF patients awaiting durable MCS or cardiac transplantation (CTx) is vital in improving both short and longer-term outcomes. This review will summarize the clinical assessment, hemodynamic profiling and management of the patient with AcHF in the ICU. The general principles of pre-surgical optimization encompassing individual systems (the kidneys, the liver, blood and glycemic control) will be discussed. Other factors impacting upon post-operative outcomes including nutrition and sarcopenia and pre-surgical skin decolonization have been included. Issues specific to durable MCS including the assessment of the right ventricle and strategies for optimization will also be discussed.
- 4 February 2020
- Published by SAGE Publications in Obstetric Medicine
- Vol. 14 (2) , 102-104
Pregnancy in a woman with a chronic descending thoracic aortic dissection
Pregnancy increases aortic wall stress and, for a woman with a chronic dissection, this can lead to extension of the dissection, aortic rupture, and death. We report a pregnancy in a woman with a history of a chronic type B aortic dissection. As a child, she had repeat balloon dilation of aortic coarctation, and one of the procedures was complicated by an iatrogenic dissection at the dilation site. At the age of 27 years, she had a planned pregnancy.
- 4 February 2020
- Published by SAGE Publications in Obstetric Medicine
- Vol. 14 (2) , 102-104
Pregnancy in a woman with a chronic descending thoracic aortic dissection
Pregnancy increases aortic wall stress and, for a woman with a chronic dissection, this can lead to extension of the dissection, aortic rupture, and death. We report a pregnancy in a woman with a history of a chronic type B aortic dissection. As a child, she had repeat balloon dilation of aortic coarctation, and one of the procedures was complicated by an iatrogenic dissection at the dilation site. At the age of 27 years, she had a planned pregnancy.
- 1 October 2019
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 40 (Supplement)
P6312Pregnancy outcomes in women with cardiothoracic transplants: a systematic review and meta-analysis
Background: Increasing numbers of women with heart-lung transplants (HLT) are now planning and continuing with pregnancies. The risks of pregnancies in these women have not been systematically assessed. Methods: A search strategy was designed for MEDLINE, EMBASE, and Cochrane Central from inception to January 2018 to identify studies reporting outcomes in three or more pregnancies following HLT. Pooled incidence of maternal outcomes and fetal and neonatal outcomes were calculated using random-effects meta-analysis and reported per 100 pregnancies with 95% confidence intervals (CI). Risk-of-bias was determined using the Joanna Briggs Checklist for Case Series. Subgroup analysis was conducted based on transplanted organ. Results: A total of 3658 records were identified, 172 full texts reviewed, and 12 studies included. The included studies reported on 385 pregnancies in 272 transplant recipients. Maternal complications included mortality during pregnancy [0.5% (0, 1.1%)], mortality during the specified follow-up period [15.4% (10,4, 20.3%)], graft rejection during pregnancy [7.4% (4.2, 10.5%)], preeclampsia [12.3% (7.2%, 17.5%)], gestational diabetes [6.4% (2.6, 10.1%)], and caesarean deliveries [41.4% (33.4, 48.7%)]. As many as 78.4% (69.8, 86.9%) pregnancies resulted in live births. Of the remainder, 13.6% (6.3, 20.9%) resulted in miscarriages (fetal loss under 20 weeks of gestation), 2% (0.3, 3.7%) resulted in stillbirths (fetal loss after 20 weeks of gestation), and 6.8% (4.3, 9.3%) in pregnancy terminations for various reasons. Of those born live, 3.4% (1.3, 5.6%) succumbed in the neonatal period. Over half the pregnancies [51.2% (31, 71.3%)] resulted in preterm deliveries (<37 weeks of gestation). There were subgroup-specific variations in the prevalence of complications. For example, lung transplant recipients were less likely than heart transplant recipients to have pregnancies complicated by preeclampsia [8.3% (3.0, 13.6%) vs. 17.8% (10.8, 24.8%)] suffer maternal mortality during the follow up period [41.4% (23.4, 59.3%) vs. 10.8% (5.9, 15.8%)]. Studies had a moderate risk-of-bias. Conclusions: Although large proportions of pregnancies in women with HLT result in live births and few maternal deaths occur during pregnancy, these women are at increased risk for preeclampsia, preterm birth, perinatal mortality and maternal mortality following childbirth. Subgroup-specific variations should be taken into account while counselling HLT recipients contemplating pregnancies. Acknowledgement/Funding: None
- 1 October 2019
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 40 (Supplement)
P6312Pregnancy outcomes in women with cardiothoracic transplants: a systematic review and meta-analysis
Background: Increasing numbers of women with heart-lung transplants (HLT) are now planning and continuing with pregnancies. The risks of pregnancies in these women have not been systematically assessed. Methods: A search strategy was designed for MEDLINE, EMBASE, and Cochrane Central from inception to January 2018 to identify studies reporting outcomes in three or more pregnancies following HLT. Pooled incidence of maternal outcomes and fetal and neonatal outcomes were calculated using random-effects meta-analysis and reported per 100 pregnancies with 95% confidence intervals (CI). Risk-of-bias was determined using the Joanna Briggs Checklist for Case Series. Subgroup analysis was conducted based on transplanted organ. Results: A total of 3658 records were identified, 172 full texts reviewed, and 12 studies included. The included studies reported on 385 pregnancies in 272 transplant recipients. Maternal complications included mortality during pregnancy [0.5% (0, 1.1%)], mortality during the specified follow-up period [15.4% (10,4, 20.3%)], graft rejection during pregnancy [7.4% (4.2, 10.5%)], preeclampsia [12.3% (7.2%, 17.5%)], gestational diabetes [6.4% (2.6, 10.1%)], and caesarean deliveries [41.4% (33.4, 48.7%)]. As many as 78.4% (69.8, 86.9%) pregnancies resulted in live births. Of the remainder, 13.6% (6.3, 20.9%) resulted in miscarriages (fetal loss under 20 weeks of gestation), 2% (0.3, 3.7%) resulted in stillbirths (fetal loss after 20 weeks of gestation), and 6.8% (4.3, 9.3%) in pregnancy terminations for various reasons. Of those born live, 3.4% (1.3, 5.6%) succumbed in the neonatal period. Over half the pregnancies [51.2% (31, 71.3%)] resulted in preterm deliveries (<37 weeks of gestation). There were subgroup-specific variations in the prevalence of complications. For example, lung transplant recipients were less likely than heart transplant recipients to have pregnancies complicated by preeclampsia [8.3% (3.0, 13.6%) vs. 17.8% (10.8, 24.8%)] suffer maternal mortality during the follow up period [41.4% (23.4, 59.3%) vs. 10.8% (5.9, 15.8%)]. Studies had a moderate risk-of-bias. Conclusions: Although large proportions of pregnancies in women with HLT result in live births and few maternal deaths occur during pregnancy, these women are at increased risk for preeclampsia, preterm birth, perinatal mortality and maternal mortality following childbirth. Subgroup-specific variations should be taken into account while counselling HLT recipients contemplating pregnancies. Acknowledgement/Funding: None
- Open Access
- 1 August 2019
- Published by Taylor & Francis in Transplant Research and Risk Management
- Vol. ume 11, 29-38
Pregnancy in heart transplant recipients – current perspectives
Successful pregnancy with a live birth and preserved graft function is possible in women following cardiac transplantation but requires careful assessment and planning in conjunction with the co-ordinated care of a specialist multidisciplinary team. Pregnancy poses significant risks to the mother, graft and foetus; these include the challenges of managing immunosuppression to avoid rejection whilst balancing the risks to the foetus from potentially teratogenic medication. This article aims to provide a contemporary perspective on the issues pertaining to pregnancy in heart transplant recipients; describing the pre-conception, pre-partum, intrapartum and postpartum management in this unique group of women.
- 1 August 2019
- Published by Taylor & Francis in Transplant Research and Risk Management
- Vol. ume 11, 29-38
Open AccessPregnancy in heart transplant recipients – current perspectives
Successful pregnancy with a live birth and preserved graft function is possible in women following cardiac transplantation but requires careful assessment and planning in conjunction with the co-ordinated care of a specialist multidisciplinary team. Pregnancy poses significant risks to the mother, graft and foetus; these include the challenges of managing immunosuppression to avoid rejection whilst balancing the risks to the foetus from potentially teratogenic medication. This article aims to provide a contemporary perspective on the issues pertaining to pregnancy in heart transplant recipients; describing the pre-conception, pre-partum, intrapartum and postpartum management in this unique group of women.